Who will transform the HAE Market?

Hereditary angioedema (HAE)—a niche rare disease market worth billions—is becoming an innovation hotspot. Ionis and KalVista promise transformative solutions. What are the pros and cons of each?

April 06, 2025

Bladder Cancer: Emerging Therapies and Key Areas to Watch

Bladder cancer: 82,000 new US cases each year and among the costliest to treat. Is a breakthrough on the horizon?

April 06, 2025

Dato-DXd: AstraZeneca and Daiichi Sankyo's Unwavering ADC Pursuit

AstraZeneca and Daiichi Sankyo's investigational antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) has encountered challenges in two pivotal Phase 3 cancer trials.

September 27, 2024

The Radiopharmaceutical Revolution

The radiopharmaceutical industry is witnessing a surge of activity and investment, underscoring the immense potential of these cutting-edge therapies in the fight against cancer.

September 27, 2024

Biotech Funding Rollercoaster: Tracking Valuation Shifts from Seed to IPO

In September, 3 biotechs IPOd on the same day, and their filings revealed an interesting insight: how much money did earlier venture investors make at the IPO?

September 25, 2024

Top 10 BioPharma Market Cap Gains: September 2023 vs. 2024

In the past 12 months, several BioPharma companies experienced substantial gains in market capitalization, driven by continued performance of GLP-1s and improved results in oncology.

September 25, 2024

Biotech IPO Trifecta: A Resurgence of Innovation and Investment

In a rare tripleheader day, three biotechnology companies successfully went public, raising a combined $750 million: Bicara Therapeutics, Zenas BioPharma, and MBX Biosciences.

September 23, 2024

Post-Keytruda: Potential Growth Drivers for Merck

As Keytruda’s LOE approaches in 2028, Merck continues to strengthen its pipeline. Here are some key developments shaping Merck's future:

September 23, 2024

Select Eli Lilly U.S. Patent Expiries

Eli Lilly has seen a growth surge thanks to the success of its GLP-1s, which enjoy patent protection well into the 2030s. The rest of its portfolio is more nuanced - here’s a closer look at key patent expiries in key therapeutic areas:

September 20, 2024